Cancer cells have a different metabolism to healthy cells.
They often divide unchecked or die more slowly.
This occurs via various processes.
Kinase inhibitors inhibit these processes by blocking protein kinases (certain enzymes) and thus interfering with the distribution of energy within the cancer cell.
They are therefore also referred to as “kinase inhibitors” or “protein kinase inhibitors”.
Other terms are tyrosine kinase inhibitor (TKI) or small molecule kinase inhibitor (smKI).
The target of kinase inhibitors are characteristics of the cancer cell that distinguish it from most healthy cells.
The effect of kinase inhibitors is therefore concentrated on the tumor.

In our practices, together with the clinics of the Asklepios Tumor Center Hamburg and the Institute for Hematopathology Hamburg, individualized or personalized cancer therapy is already being practiced intensively.
The entire spectrum of immunological markers and molecular genetic alterations is analyzed at the time of the initial diagnosis of cancer, so that targeted tumor therapy can be started as an initial therapy if necessary.
Classic chemotherapies are increasingly losing importance in cancer treatment in favor of new molecular and immunological approaches, but are still too often used “up front”.
Regular participation in the organ-specific tumor conferences of the Asklepios Tumor Center Hamburg ensures precise intersectoral cooperation between our practices and the clinics and seamless digital information transfer, which provides our patients with the most up-to-date therapy and guarantees coverage of costs by health insurance companies, even for highly innovative drugs, some of which have not yet been approved in Germany.